1.1
Use selective internal radiation therapy (SIRT) as an option for neuroendocrine tumours that have metastasised to the liver, with standard arrangements in place for clinical governance, consent and audit.
Guidance
1 Recommendations
1 Recommendations
1.2
Patient selection should be done by a multidisciplinary team with experience in managing neuroendocrine tumours.
1.3
The procedure should only be done in specialist centres by clinicians trained and experienced in delivering SIRT.
1.4
Clinicians should enter details about everyone having this procedure into an appropriate registry.
Why the committee made these recommendations
The evidence shows that SIRT controls the growth of tumours that have metastasised to the liver, and reduces symptoms. There can be serious complications with SIRT, but these are well-recognised and infrequent. For some people with these tumours, SIRT may be better tolerated than other available treatment options. More evidence would help to define which people would benefit the most.